Quick Answer
Evommune, Inc. reported Stockholders Equity of $205.57 million for fiscal year 2025.
Evommune, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $205.57M | +242.5% |
| 2024 | -$144.24M | -85.6% |
| 2023 | -$77.71M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$183.14M | -49.5% | -7.0% |
| June 30, 2025 | -$171.23M | -60.0% | -18.7% |
| December 31, 2024 | -$144.24M | -85.6% | -17.7% |
| September 30, 2024 | -$122.53M | — | -14.5% |
| June 30, 2024 | -$107.03M | — | -37.7% |
| December 31, 2023 | -$77.71M | — | — |
- Evommune, Inc. showed an increase of +242.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2023–2025 period, Evommune, Inc.’s stockholders equity has grown by 364.5% (from -$77.71 million to $205.57 million).
- The most recent figure is from Evommune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: